Medicus Pharma (NASDAQ:MDCX) Announces Quarterly Earnings Results, Misses Estimates By $0.07 EPS

Medicus Pharma (NASDAQ:MDCX) announced its quarterly earnings data on Wednesday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07), Zacks reports.

Medicus Pharma Price Performance

Shares of Medicus Pharma stock traded down $0.01 during trading hours on Wednesday, hitting $0.33. The company’s stock had a trading volume of 1,099,044 shares, compared to its average volume of 3,489,210. The company has a market capitalization of $18.76 million, a PE ratio of -0.12 and a beta of 0.12. The stock has a 50 day moving average of $0.37 and a 200 day moving average of $0.55. Medicus Pharma has a 12 month low of $0.25 and a 12 month high of $3.05.

Institutional Trading of Medicus Pharma

A number of large investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new stake in Medicus Pharma in the 2nd quarter valued at approximately $41,000. Osaic Holdings Inc. lifted its position in shares of Medicus Pharma by 180.0% in the second quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after purchasing an additional 9,000 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Medicus Pharma in the third quarter worth $59,000. HRT Financial LP acquired a new position in Medicus Pharma during the fourth quarter worth $42,000. Finally, Commonwealth Equity Services LLC grew its position in Medicus Pharma by 161.8% in the fourth quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock valued at $44,000 after purchasing an additional 17,611 shares in the last quarter.

Analyst Upgrades and Downgrades

Several analysts have commented on MDCX shares. Alliance Global Partners initiated coverage on shares of Medicus Pharma in a research report on Tuesday, July 28th. They set a “buy” rating for the company. Roth Capital initiated coverage on Medicus Pharma in a report on Tuesday, April 21st. They issued a “buy” rating for the company. D. Boral Capital restated a “buy” rating and set a $9.00 target price on shares of Medicus Pharma in a report on Monday, April 20th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Medicus Pharma in a research report on Wednesday, July 8th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $9.00.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.